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Background: Following chemo-radiotherapy (CCRT) for human papilloma virus positive (HPVþ ) locally advanced head and neck
cancer, patients frequently undergo unnecessary neck dissection (ND) and/or repeated biopsies for abnormal PET-CT, which
causes significant morbidity. We assessed the role of circulating HPV DNA in identifying ‘true’ residual disease.
Methods: We prospectively recruited test (n¼ 55) and validation (n¼ 33) cohorts. HPV status was confirmed by E7 RT-PCR. We
developed a novel amplicon-based next generation sequencing assay (HPV16-detect) to detect circulating HPV DNA. Circulating
HPV DNA levels post-CCRT were correlated to disease response (PET-CT).
Results: In pre-CCRT plasma, HPV-detect demonstrated 100% sensitivity and 93% specificity, and 90% sensitivity and 100%
specificity for the test (27 HPVþ ) and validation (20 HPVþ ) cohorts, respectively. Thirty-six out of 37 patients (test and validation
cohort) with complete samples-set had negative HPV-detect at end of treatment. Six patients underwent ND (3) and repeat
primary site biopsies (3) for positive PET-CT but had no viable tumour. One patient had positive HPV-detect and positive PET-CT
and liver biopsy, indicating 100% agreement for HPV-detect and residual cancer.
Conclusions: We demonstrate that HPV16-detect is a highly sensitive and specific test for identification of HPV DNA in plasma at
diagnosis. HPV DNA post-treatment correlates with clinical response.
Organ-preserving, concomitant, cisplatin-based chemoradiother-
apy (CCRT), followed by surgical salvage if required, is a standard-
of-care for locally advanced (stage III/IV disease) head and neck
cancer (LAHNC) of the oropharynx, larynx and hypopharynx
(Dillon and Harrington, 2015). Following radical CCRT, decisions
regarding salvage surgery for residual primary and cervical lymph
node disease are based on clinical examination and imaging.
18F-FDG PET-CT, when available, is the imaging modality of
choice (Mehanna et al, 2016), with a negative predictive value in
excess of 90% (Abgral et al, 2009; Mehanna et al, 2016). However,
the positive predictive value is sub-optimal and patients frequently
undergo unnecessary neck dissection (ND; Hamoir et al, 2012)
and/or repeated biopsies from the purportedly residual primary
tumour. ND causes significant morbidity (fibrosis, facial/
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hypoglossal nerve damage, reduced shoulder movement and
swallowing problems) and repeated biopsies to rule out residual
cancer at the primary site can lead to delayed mucosal healing and
significant patient anxiety. Therefore, optimised predictors of
residual disease are required as a means of guiding management
decisions.
A proportion of LAHNC are causally related to the human
papilloma virus (HPV; Schache et al, 2016). In the tumour, HPV
DNA is integrated into the host genome or is present in episomal
form (Hopman et al, 2004) and can be released in to the
bloodstream. Circulating HPV DNA can potentially be used as a
detection marker for HPV-related LAHNC. The utility of
circulating HPV DNA in monitoring disease response following
radical chemo-radiotherapy in LAHNC has not been extensively
evaluated. In a retrospective study, Wang et al (2015) measured
circulating tumour DNA in of 93 patients with head and neck
cancer at various sub-sites 21 of whom had HPV positive (HPVþ )
LAHNC. Very limited correlative analyses were performed
between circulating DNA and treatment response.
Here, we prospectively collected plasma DNA in a test and
independent validation cohorts of homogeneous group of patients
with LAHNC treated with primary chemo-radiotherapy. We
developed an ultra-sensitive HPV DNA next generation sequen-
cing (NGS) assay ‘HPV16-detect’, with the ability to detect HPV
DNA. We demonstrate that HPV16-detect analysis in the post-
treatment samples in test and validation cohorts correlates with
clinical response following curative treatment for LAHNC, and can
anticipate residual disease.
MATERIALS AND METHODS
Informed consent was obtained from all eligible patients with stage
III/IV (AJCC 2007) squamous cell carcinoma of the oropharynx,
larynx or hypopharynx. Institutional board (ref. no. CCR 4157)
and ethics committee (ref. no. 14/NE/1055) approved the study.
Patients o71 years old received CCRT (cisplatin, 100mgm 2
days 1 and 29; Wilkins et al, 2013). Patients staged as having T4
and/or N2C/N3 disease and deemed medically fit received
induction chemotherapy, IC (2 cycles of taxotere (75mgm 2,
cisplatin 75mgm 2, d1 and 5-fluorouracil 750mgm 2 d1-5)
followed by CCRT (Blanchard et al, 2013). Radiotherapy was
delivered using a simultaneous integrated boost-IMRT technique
as described previously (Bhide et al, 2007). Clinical target volume
(CTV) 1 included primary tumour and involved lymph node
groups. CTV2 included areas at risk of harbouring microscopic
disease and elective lymph node groups. All patients were treated
with doses of 65Gy in 30 fractions (2.17Gy/fraction) over 6 weeks
to the primary target. Doses to the elective target were 54Gy in 30
fractions (1.8Gy/fraction) over 6 weeks. A single observer
delineated gross tumour volumes for primary disease and lymp
nodes based on pre-treatment 18F-FDG PET-CT and MRI.
At 12 weeks, response following treatment was assessed by
clinical examination and 18F-FDG PET-CT. Patients with meta-
bolically active lymph node disease alone on 18F-FDG PET-CT
underwent ND. Residual or equivocal uptake at primary and
distant sites was confirmed with a biopsy.
Validation samples were obtained from patients in an
independent prospective observational clinical trial of imaging in
LAHNC (CCR no. 3926, Ethics ref. no. 13/LO/0067). The patients
(Supplementary Table S1) had to fulfil the same eligibility criteria,
underwent treatment and response assessment as described above.
Serial plasma samples were collected were collected at baseline
(before IC or CCRT), pre-CCRT (in patients receiving IC), 6 weeks
and 12 weeks following completion of treatment and at the time of
further 18F-FDG PET-CT scan if indicated.
Blood samples: plasma processing and DNA extraction. 20ml
of blood was centrifuged at 1500 r.p.m. for 10min within 3 h of
collection. Plasma was isolated and frozen at  80 1C. Prior to
extraction, plasma samples were further centrifuged at
14 000 r.p.m. for 10min at 4 1C. DNA was extracted from 5ml
of plasma using the QIAamp Circulating Nucleic Acid Kit
(Qiagen, Hilden, Germany) according manufacturer’s instruc-
tions. DNA was eluted in 50 ml of AVE buffer and stored at
 20 1C. For the validation cohort, circulating DNA was
extracted from 2ml of plasma using the MagMAX Cell-free
DNA Isolation kit (ThermoFisher Scientific, Waltham, MS,
USA) on a KingFisher Flex System (ThermoFisher Scientific)
according to the manufacturer’s instructions. The resulting DNA
was eluted in 50 ml of MagMAX Cell-free DNA Elution Solution.
Plasma DNA was quantified using a Bio-Rad QX200 ddPCR
system- using ribonuclease P as a reference gene as previously
described (Garcia-Murillas et al, 2015).
Tumour biopsies: HPV16 detection in tumour. Formalin fixed
paraffin embedded tumour blocks of the diagnostic biopsy samples
were obtained. Ten 10 mm unstained slides and two haematoxylin
and eosin stained slides were obtained from representative FFPE
blocks. Experienced pathologists assessed tumour content and
cellularity and suitable areas of tumour were marked for macro-
dissection, if necessary. RNA was extracted using the RecoverAll
Total Nucleic Acid isolation kit for FFPE (Thermo Fisher,
Waltham, MS, USA) followed by cDNA synthesis using the
High-Capacity cDNA Reverse Transcriptase kit (Thermo Fisher).
Evidence of HPV integration was assessed by detection of E7
expression using methods and primers described previously
(Lamarcq et al, 2002) in a 7500 Sequence detection system
(Applied Biosystems, Foster City, CA, USA/Thermo Fisher). Any
specimen producing a dCt o13 was consider positive for HPV
integration.
P16 status of tumours was confirmed using immunohistochem-
istry (details Supplementary Section). All immunohistochemical
interpretations were made by consultant head and neck histo-
pathologists. Diffuse strong nuclear expression of470% of tumour
nuclei for p16 was considered positive.
Table 1. Patient and tumour characteristics for the test cohort
Variable Number of cases
Number of patients 55
T-stage
1 6
2 25
3 15
4 9
N-stage
0 7
1 6
2A 2
2B 28
2C 12
Treatment
ICþCCRT 12
CCRT 43
Pack-years (includes ex smokers)
Non-smoker 15
p10 11
410 29
Tumour sub-site
Oropharynx 47
Larynx 4
Hypopharynx 4
Abbreviations: IC¼ induction chemotherapy; CCRT¼ cisplatin-based chemoradiotherapy.
BRITISH JOURNAL OF CANCER Plasma HPV DNA for response prediction in head and neck cancer
2 www.bjcancer.com |DOI:10.1038/bjc.2017.258
HPV16 DNA sequencing in tumour and plasma (HPV16-detect
assay design). To detect HPV DNA in patients we designed
‘HPV16-detect’ a novel NGS assay using Ion Ampliseq Designer
(ThermoFisher Scientific). This comprised of a 39-amplicon single
pool panel covering 34 distinct regions of the HPV16 genome,
covering nucleotide variations in the most prevalent HPV16
subtypes (Burk et al, 2013; Cullen et al, 2015) and human reference
genes (5 amplicons). Seven of the most prevalent strains of HPV16
(Burk et al, 2013; Cullen et al, 2015) were aligned using CLUSTAL
O (1.2.1) multiple sequence alignment programme (ebi.ac.uk).
Common regions surrounding base differences between the
different strains were used to guide the design of the panel.
Human sequences (exon 8 of GAPDH and exon 4 of ACTINB)
were also included in the panel design as controls for library
preparation and sequencing efficiency. Ion torrent libraries
were prepared using Ion Ampliseq library preparation kit 2.0
(ThermoFisher Scientific) according to manufacturer’s instructions
using 5 ng of tissue DNA or 3 ng of plasma DNA. Plasma DNA was
quantified as per the method detailed in the Supplementary
Section. The barcoded libraries were quantified using the Ion
Library TaqMan Quantitation kit before dilution to 100 pM and
pooling. Libraries were templated using the Proton Hi-Q
templating kit on the Ion Chef and sequenced using a Proton PI
Chip v2 and 520 flows. The average amplicon length was 136 bases
and the genome size was 8964 bp (including the human
amplicons). The sequencing ranged between B100 000–
14 000 000 reads per sample.
The sequencing data were aligned using the TorrentCaller
aligner TMAP to an amalgamated HPV16 genome (accession no.
K02718) with the human exons included. Bedtools v2.23.0
(Quinlan and Hall, 2010) was used to extract on-target reads with
a minimum overlap of 50% with amplicons in the panel.
Additionally reads with a mapping quality of o15 were removed
using samtools v1.2 (Li et al, 2009).
From the cleaned bam files, coverage was calculated for each
amplicon in the panel using coverage Bed. Reads were split into
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Figure 1. Comparison of HPV16 status by E7 mRNA, p16 staining and HPV16-detect (NGS) assay in tissue and plasma. (A) There was 100%
agreement between the HPV16 status assigned by the ‘gold standard’ E7 mRNA expression and HPV16-detect. (B) Test cohort: HPV16-detect
assay demonstrated 100% sensitivity and 92.9% specificity in detecting HPV DNA in plasma compared to tissue. (C) Validation cohort: HPV16-
detect assay demonstrated 90% sensitivity and 100% specificity in assigning HPV status in plasma compared to p16 staining in tissue.
NPV¼ negative predictive value; PPV¼positive predictive value.
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those covering human and those covering HPV amplicons and
coverage of each portion calculated individually.
To validate NGS detection of HPV DNA with HPV16-detect, we
compared NGS HPV16 detection with E7 mRNA detection by RT-
PCR, considered as the ‘gold-standard’ assay for biologically relevant
HPV infection (Schache et al, 2011). Baseline and post-CCRT
plasma samples from HPV16þ patients in the test cohort were then
sequenced using HPV16-detect. Presence of plasma HPV DNA was
correlated to disease response following treatment. A similar
methodology was used for the independent validation cohort, except
for tumour HPV assignment, which based on P16INK4A alone, to
mirror current clinical practice. Analysis of plasma HPV DNA was
performed blind to the patients HPV status and disease response.
Statistical analyses. Correlation analysis was used to quantify the
relationship between: plasma HPV DNA levels at baseline with
tumour volumes. Comparisons between different HPV16 assays in
different tissue types were analysed using contingency diagrams
and Fisher’s exact test. All statistical analyses were calculated in
GraphPad Prism version 6.
In order to classify HPVþ and HPV- samples using HPV16-
detect in tissue, we set a threshold whereby a sample was classified
positive if there were 10 reads present from more than 10 different
HPV16 amplicons. For the experimental cohort, human reads ranged
between B6000–72 000 and 57 000–3 000 000 for tissue and plasma,
respectively. Thus, a minimum threshold of 50 000 reads in the
human amplicons was set for the plasma validation cohort to account
for library preparation and sequencing efficiency. In order to assess
the threshold for the number of amplicons needed for positive
HPV16-detect readout in plasma–a ROC analyses was used. In the
first step, HPV status was assigned using the gold standard E7 mRNA
to separate the two groups. The number of amplicons with410 reads
at baseline was inputted for each patient to find a suitable threshold
for this parameter. Sorting the values in both HPV positive and
negative groups and averaging adjacent values in the sorted
list generated a list of thresholds. Based on the ROC analyses a
threshold of 10 reads in 7 amplicons gave the greatest sensitivity and
specificity and was selected as threshold for classification of plasma as
HPV DNA positive Supplementary Figure S2 and Supplementary
Table S2).
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Figure 2. HPV DNA tracking in treatment responsive HPVþ patients using the HPV16-detect assay. HPV DNA levels decreased below threshold
at 12-weeks post-treatment in patients receiving C-CRT (n¼ 19, A) and in patients who received induction chemotherapy (IC) and CRT (n¼7, B).
Red plots in (A) highlight the three patients in (C–E). Residual disease was evident in three patients by 18F-FDG PET-CT (C–E), with negative
biopsies and below threshold levels of HPV DNA in the plasma taken at the time of biopsies (PA). PA¼post-assessment; post-IC¼post-induction
chemotherapy. A full colour version of this figure is available at the British Journal of Cancer journal online.
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RESULTS
Fifty-nine patients were recruited into the study. Details for 55 (4
withdrew consent) patients are shown in Table 1. Tumour blocks
were not available in five patients. Adequate DNA and RNA could
be extracted from the tumour blocks of 42/50 patients. Twenty-
seven samples were positive for E7 (and p16INK4A) and these
patients were classed as HPVþ . All of these patients had cancers
of the oropharynx.
Validation of HPV16-detect. Detection of HPV DNA with
HPV16-detect was correlated with E7 mRNA detection for
validation and demonstrated 100% specificity (95% confidence
interval (CI) 76.84–100%) and sensitivity (95% CI 87.23–100%;
Po0.0001, Figure 1A).
Sequencing of baseline plasma samples from the 27 HPVþ
patients using HPV16-detect demonstrated sensitivity and speci-
ficity of 100% (95% CI 87.23–100%) and 92.9% respectively
(95% CI 66.13–99.82%), (Po0.0001, Figure 1B). HPV DNA was
not detected in any of the thirteen patients with HPV– tumours,
who served as a negative control (Supplementary Figure S1). There
was no correlation between the volumes of disease (primary and
lymph nodes) and HPV DNA levels in plasma (Supplementary
Table S3).
The validation cohort had 33 patients (Supplementary Table
S1). Using HPV16-detect, HPV DNA was detected in the baseline
plasma of 18 of the 20 patients HPVþ patients (on p16INK4A IHC)
but not in negative controls (HPV-patient samples; Figure 1C and
Supplementary Figure S1). This gave a sensitivity and specificity of
90% (95% CI 68.30–98.77%) and 100%, (95% CI 75.29–100%)
respectively (Po0.0001, Fisher’s exact test, Figure 1C).
HPV DNA tracking for HPVþ tumours to identify residual
disease. Twenty-three (including the two HPVþ patients with
PIK3CA mutation) of the 27 HPVþ patients had complete
radiological response as assessed by 18F-FDG PET-CT at 12 weeks
post-CCRT. HPV DNA levels were below the threshold of
detection in all 23 patients (Figure 2A and B). Three of the four
remaining patients had increased 18F-FDG uptake corresponding
to the primary site (Figure 2C–E). Biopsies from the PET-avid sites
failed to demonstrate residual tumour. Further 18F-FDG PET-CT
scans demonstrated complete resolution of disease. HPV DNA
levels remained below the threshold of detection at all time points.
In one patient 18F-FDG PET-CT demonstrated increased 18F-
FDG uptake in the liver, but no active disease at the primary site or
cervical lymph nodes with elevated HPV DNA levels (Figure 3).
The single biopsy-proven (HPVþ ) liver lesion was surgically
resected, resulting only in a marginal fall in plasma HPV DNA
levels. Further 18F-FDG PET-CT failed to demonstrate any disease.
However, plasma HPV DNA levels showed a continued rise and
18F-FDG PET-CT, performed 8 months following liver resection,
demonstrated increased uptake in the cervical lymph nodes. The
presence of recurrent neck disease was confirmed at ND.
One patient with p16INK4A IHC-positive tumour with inade-
quate tumour RNA for E7 analysis (therefore not included in the
27 HPVþ patient cohort) had increased 18F-FDG PET-CT uptake
in a level II node and underwent ND, which failed to show any
viable tumour. HPV DNA was detectable in baseline plasma but
undetectable in plasma sample prior to ND.
Ten of the twenty HPVþ patients in the validation cohort had
complete sets of serial plasma samples. HPV DNA was not
detected at 12 weeks post-CCRT in any of these 10 patients
(Figure 4A). Seven these patients had complete radiological
response on 18F-FDG PET-CT. Three patients with increased
18F-FDG uptake in cervical lymph nodes underwent ND and, as
with the patient in the test cohort, the specimen showed no
evidence of viable tumour (Figure 4B–D).
DISCUSSION
We describe ‘HPV16-detect’, a novel ultra-sensitive method of
detecting and tracking HPV DNA in HPVþ LAHNC in a study
with prospective collection of biological samples and detailed
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Figure 3. HPV16-detect assay tracked presence of residual disease with 18F-FDG PET-CT at corresponding time points. HPV DNA levels
decreased in response to treatment at 6 weeks, but increased significantly at 12 weeks, which corresponded to presence of liver metastases on
18F-FDG PET-CT. HPV DNA levels decreased post-liver resection, however never dropped below the threshold. 18F-FDG PET-CT 8 months
following liver surgery revealed disease relapse in cervical lymph nodes. CRT¼ chemo-radiotherapy; PA¼post-assessment; post-IC¼post-
induction chemotherapy. A full colour version of this figure is available at the British Journal of Cancer journal online.
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clinical data. Amplicon-based sequencing of multiple regions of the
viral genome enabled us to detect HPV DNA at baseline with high
sensitivity and specificity. Tracking HPV DNA in sequential
samples through and after chemo-radiotherapy predicted response
and residual disease at the primary site and in cervical lymph
nodes suggesting the potential of HPV16-detect to enhance clinical
decision-making and in avoiding unnecessary surgical procedures.
These findings were confirmed in a separate prospective validation
cohort.
Wang et al retrospectively measured, ctDNA in saliva (n¼ 93)
and plasma (n¼ 47) of 93 patients with head and neck cancer of
whom 73 had LAHNC. ctDNA (n¼ 84) and HPV DNA (n¼ 21)
was quantified in plasma at a single time point in the majority of
patients using personalised PCR and E7 digital PCR, respectively.
HPV DNA was detected in plasma in 86% (18/21) of HPVþ
patients (Wang et al, 2015). However, post-treatment monitoring
of HPV DNA was not reported. Dahlstrom et al (n¼ 114), Cao
et al (n¼ 40) and Ahn et al (n¼ 52) used E6 and/or E7 PCR for
plasma HPV DNA measurement following confirmation of HPV
status in tumour (E7 RNA). HPV DNA at baseline was respectively
detected in 60%, 65% and 67% of HPVþ patients (Cao et al, 2012;
Ahn et al, 2014; Dahlstrom et al, 2015). Mazurek et al based the
diagnosis of HPVþ LAHNC solely on the presence of plasma
HPV DNA quantified using E6/E7 PCR. The detection rate in that
study was 14% (Mazurek et al, 2016). Studies have also attempted
to quantify HPV DNA in saliva of HPV patients with LAHNC.
However, the detection rate at baseline is between 40 and 55% and
inferior to that of plasma (Ahn et al, 2014; Rettig et al, 2015; Wang
et al, 2015). Measuring plasma HPV DNA using targeted deep
sequencing (HPV16-detect) with greater coverage of HPV DNA,
may have greater sensitivity and specificity compared to other PCR
based assays that focus on integrated E6 or E7 (Cao et al, 2012;
Dahlstrom et al, 2015; Jeannot et al, 2016; Mazurek et al, 2016) as
demonstrated in our study.
Standard-of-care radiological examination is undertaken 10–12
weeks following CCRT, assuming that disease will have reached
maximal response at this time point. However, Huang et al (2013)
showed that temporal regression of tumour in lymph nodes in
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Figure 4. HPV DNA tracking in the validation cohort with HPV16-detect assay. HPV DNA levels decreased below threshold at 12-weeks post-
treatment (n¼10, A). Red plots in (A) highlight the three patients in (B–D) with residual lymph node disease on 18F-FDG PET-CT, negative ND
specimens and below threshold levels of HPV DNA in the plasma taken at the time ND. PA¼post-assessment; post-IC¼post-induction
chemotherapy; Post-1 week¼post-5 fractions of radiotherapy. A full colour version of this figure is available at British Journal of Cancer journal
online.
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HPVþ patients following CCRT might be significantly more
prolonged. Biopsies from three patients in our study who had
undetectable HPV DNA and persistent 18F-FDG uptake and at the
primary site at the 12 week time point failed to show residual
tumour with subsequent resolution of 18F-FDG uptake, suggesting
that some HPV-driven primary tumours exhibit prolonged
temporal regression, similar to that seen in lymph node disease.
(Figure 2C–E). In addition, plasma HPV DNA levels of can serve
as a predictive marker of residual disease in this setting and prevent
unnecessary biopsies and the anxiety associated with uncertainty
about disease response.
Currently, patients with residual disease (increased 18F-FDG
uptake; Mehanna et al, 2016) at 10–12 weeks, are considered for
salvage surgery for the primary tumour and/or residual lymph
nodes. One patient in the test and 3 patients in the validation
cohort were deemed to have residual lymph node disease on 18F-
FDG PET-CT and underwent ND, without evidence of viable
tumour on pathological examination. Plasma HPV DNA was
undetectable in all four patients at the time of radiological
examination. The randomized phase III PET-NECK study
reported a severe surgical complication rate of 20–26% following
ND (Mehanna et al, 2016). In addition, on long-term follow-up,
ND following CCRT results in significant fibrosis and reduction
in shoulder movement and has an adverse impact on QOL (Shah
et al, 2001). Furthermore, HPVþ patients are younger and due
to the excellent treatment outcomes with the current treatments
are expected to carry the burden of treatment related toxicity for
life. Over the last few decades, incidence of HPVþ LAHNC has
significantly increased and is projected to increase by up to
230% in the near future (Mehanna et al, 2013; Schache et al,
2016). Treatment dilemmas’ as a result of ‘false positive’ 18F-
FDG PET-CT will be increasingly common at tumour board
meetings. Incorporating measurement of plasma HPV DNA into
the management algorithm as a predictor of ‘true’ residual
disease has significant potential to guide treatment decisions and
avoid unnecessary surgical procedures and their attendant
morbidity.
HPV-driven LAHNC’s demonstrate very good response rates to
CCRT and only a single patient in our study had residual disease
with high levels of HPV DNA. Similarly, HPV DNA was present in
samples of small number of patients with residual or recurrent
disease in studies by by Cao et al (3 out of 4 patients) and Ahn et al
(5 out of 6 patients), where post-treatment plasma samples were
available (Cao et al, 2012; Ahn et al, 2014). In the single patient in
our study and the study by Cao et al HPV DNA levels were
elevated prior to clinically and radiologically detected metastatic
disease. In patients with clinical remission under surveillance, more
sensitive surveillance strategies using HPV DNA can potentially
detect disease relapse before it becomes clinically apparent and can
improve the probability of radical salvage therapy.
Our findings require validation in a larger cohort of patients
with longer follow-up to help establish the role of HPV16-detect in
this setting. Our assay could be used for HPV DNA measurement
in other HPV related cancers such as cancers of the cervix, anal
canal and penis and pilot studies in patients with cancers at these
sites are currently underway at our institution. Clinical trials of
treatment de-escalation in HPV-driven tumours are underway and
new studies are being planned (Masterson et al, 2014). Such studies
require confirmation of HPV as the oncogenic driver, which is
currently performed using a combination of p16INK4A over-
expression on IHC and HPV DNA in situ hybridisation on
diagnostic tumour blocks, which have a combined sensitivity and
specificity of 88% and 90%, respectively (Schache et al, 2011). Our
assay performed on an easily obtained venous sample, with higher
specificity and sensitivity, may provide a more practical alternative.
In conclusion, present preliminary results of a novel highly
sensitive and specific NGS HPV16-detect assay for detection of
HPV DNA in HPVþ patients with non-metastatic LAHNC. In
addition, we provide proof of principle that HPV DNA can
potentially be used as a predictive biomarker of disease response at
the primary site and cervical lymph nodes, following radical
treatment for LAHNC, thus avoiding unnecessary surgery.
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